For the first time since records began, not a single young woman in England who received the HPV vaccine at school has died from cervical cancer. That’s not a projection or a target. That’s the reality, right now.
A landmark study published this week confirms that cervical cancer deaths among women who were offered the human papillomavirus jab as schoolgirls have effectively hit zero. The vaccination programme, introduced in 2008 for girls aged 12 to 13, has done what researchers hoped it would do, and then some.
The numbers are striking. Researchers found that the vaccine prevented an estimated 450 cancers and 17 deaths in England alone. Among women born between 1995 and 1999, who were among the first to receive the jab, cervical cancer rates have dropped by 87 percent compared to unvaccinated generations.
“This is the result of a long-term investment in young people’s health,” one of the study’s researchers noted, adding that the findings represent “the closest thing to a success story” public health has seen in a generation.
The HPV vaccine works by protecting against the strains of human papillomavirus most commonly linked to cervical cancer. It doesn’t just reduce risk; it very nearly eliminates it when given before exposure to the virus.
What makes this particularly significant is the timeline. Cancers caused by HPV can take decades to develop, which means we’re only now beginning to see the full impact of that 2008 rollout. The girls who queued up in school halls for their jab are now women in their late twenties and early thirties, and the data is following them.
The UK has long had one of the stronger HPV vaccination programmes in the world, with uptake hovering around 80 to 85 percent in the early years. That coverage matters enormously; it’s what allows a virus to be suppressed across a whole population, not just in individuals.
The programme has since been extended to boys too, broadening the protection further and reducing transmission across the board.
It’s tempting to call this job done. But with vaccination rates in some parts of England still lagging, and global uptake deeply uneven, the harder question might be: how many more lives could be saved if the rest of the world had access to the same?
